NOVEL, SPECIFIC NUCLEIC ACID CLEAVAGE AGENTS

Information

  • Research Project
  • 3498631
  • ApplicationId
    3498631
  • Core Project Number
    R43GM046143
  • Full Project Number
    1R43GM046143-01
  • Serial Number
    46143
  • FOA Number
  • Sub Project Id
  • Project Start Date
    1/15/1991 - 35 years ago
  • Project End Date
    10/15/1991 - 34 years ago
  • Program Officer Name
  • Budget Start Date
    1/15/1991 - 35 years ago
  • Budget End Date
    10/15/1991 - 34 years ago
  • Fiscal Year
    1991
  • Support Year
    1
  • Suffix
  • Award Notice Date
    2/7/1991 - 35 years ago
Organizations

NOVEL, SPECIFIC NUCLEIC ACID CLEAVAGE AGENTS

In this Phase I study we will improve the efficiency and develop the linking chemistry of a novel class of DNA cleavage reagents. These agents, which undergo thermally triggered radical formation will be modified with an intercalating group in order to increase the efficiency of DNA cleavage. The thermal cleavers can be prepared using well established synthetic routes which provide ready access to a wide variety of derivatives. The length of the linker arm between the intercalator and the cleaver will be one structural variable examine. These compounds will be tested as footprinting agents, useful tools in molecular biology relevant to the study of molecular recognition. Sequence specificity and efficiency of cleavage will be examined under a variety of temperatures and reaction conditions. Base sequence specificity will vary according to the nature of the acridine intercalator chosen. The effect of linker arm length on efficiency of cleavage will be optimized with the aid of computer assisted molecular design. Another aim of this Phase I study is to prepare thermally triggered cleavage agents with electrophilic groups capable of reaction with nucleophilic oligonucleotides. The reaction of these highly reactive compounds with model nucleophilic will be examined. These experiments constitute a feasibility study for the development of the thermally triggered cleavage agents as oligonucleotide targeted affinity cleavage agents (Phase II). Such sequence specific DNA cleaving agents should be especially effective as antisense inhibitors of gene expression and, as such, have utility as anticancer or anti-infective drugs.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    EPOCH BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BOTHELL
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    980213906
  • Organization District
    UNITED STATES